8-K Announcements
6Material company update
May 14, 2026·SEC
Material company update
May 13, 2026·SEC
Material company update
May 6, 2026·SEC
Bionano Genomics, Inc.(BNGO)Earnings, Financials & Key Ratios
BNGO•NASDAQ
Price updated Jun 19, 2026
SectorHealthcareIndustryDiagnostics & ResearchSub-IndustryLife Science Instruments and Sequencing Tools
AboutBionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.Show more
- Revenue$29M-7.4%
- EBITDA-$24M+73.7%
- Net Income-$26M+76.4%
- EPS (Diluted)-4.85+94.5%
- Gross Margin21.95%+1677.9%
- EBITDA Margin-82.81%+71.6%
- Operating Margin-116.95%+65.4%
- Net Margin-92.59%+74.6%
- ROE-66.15%+61.2%
BNGO Key Insights
Bionano Genomics, Inc. (BNGO) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 27.4%
- ✓Trading at only 0.1x book value
✗Weaknesses
- ✗Negative free cash flow
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when BNGO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BNGO Price & Volume
Bionano Genomics, Inc. (BNGO) stock price & volume — 10-year historical chart
Loading chart...
BNGO Growth Metrics
Bionano Genomics, Inc. (BNGO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years27.37%
3 Years0.84%
TTM0.96%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM62.25%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM89.87%
Return on Capital
10 Years-160.16%
5 Years-80.17%
3 Years-106.98%
Last Year-74.11%
BNGO Recent Earnings
Bionano Genomics, Inc. (BNGO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.76+13.6%
$0.88
Rev
$7M+1.8%
$7M
Q2 2026
Mar 23, 2026Metric
Actual
Est
EPS
$0.03+96.3%
$0.81
Rev
$8M+0.9%
$8M
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$1.59+12.2%
$1.81
Rev
$7M-6.7%
$8M
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$1.99+26.0%
$2.69
Rev
$7M-6.8%
$7M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.76vs $0.88+13.6% | $7Mvs $7M+1.8% |
| Q2 2026 | Mar 23, 2026 | $0.03vs $0.81+96.3% | $8Mvs $8M+0.9% |
| Q4 2025 | Nov 13, 2025 | $1.59vs $1.81+12.2% | $7Mvs $8M-6.7% |
| Q3 2025 | Aug 14, 2025 | $1.99vs $2.69+26.0% | $7Mvs $7M-6.8% |
Based on last 12 quarters of dataView full earnings history →
BNGO Peer Comparison
Bionano Genomics, Inc. (BNGO) competitors in Life Science Instruments and Sequencing Tools — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PACB | 434.84M | 1.40 | -0.77 | 3.89% | -80.34% | -488.45% | 141.98 | |
 CDNA | 1.35B | 26.18 | -65.45 | 13.79% | -1.98% | -2.61% | 0.06 | |
 NTRA | 33.14B | 231.41 | -152.24 | 35.9% | -9.05% | -15.13% | 0.13 | |
 ILMN | 24.6B | 161.93 | 29.71 | -0.78% | 19.43% | 32.84% | 0.94 | |
 EXAS | 20.02B | 104.91 | -95.37 | 17.69% | -6.4% | -8.66% | 1.05 | |
 VCYT | 4.28B | 53.63 | 65.40 | 16.01% | 16.25% | 6.86% | 0.03 | |
 TMO | 172.66B | 464.61 | 26.19 | 3.91% | 15.18% | 13.23% | 0.76 | |
 DHR | 125.4B | 177.17 | 35.15 | 2.9% | 14.89% | 7.06% | 0.35 |
Compare BNGO vs Peers
Bionano Genomics, Inc. (BNGO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BNGO Income Statement
Bionano Genomics, Inc. (BNGO) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 9.51M | 12M | 10.13M | 8.5M | 17.98M | 27.8M | 36.12M | 30.78M | 28.51M | 28.74M |
Revenue Growth % | 39.93% | 26.26% | -15.59% | -16.06% | 111.47% | 54.62% | 29.9% | -14.79% | -7.37% | 0.96% |
Cost of Goods Sold | 6.03M | 8.71M | 6.77M | 5.73M | 14.11M | 21.86M | 26.55M | 30.4M | 22.25M | 15.24M |
COGS % of Revenue | 63.45% | 72.59% | 66.82% | 67.39% | 78.45% | 78.62% | 73.51% | 98.77% | 78.05% | - |
Gross Profit | 3.47M▲ 0% | 3.29M▼ 5.3% | 3.36M▲ 2.2% | 2.77M▼ 17.5% | 3.87M▲ 39.7% | 5.95M▲ 53.5% | 9.57M▲ 60.9% | 380K▼ 96.0% | 6.26M▲ 1546.8% | 13.5M▲ 0% |
Gross Margin % | 36.55% | 27.41% | 33.18% | 32.61% | 21.55% | 21.38% | 26.49% | 1.23% | 21.95% | 46.97% |
Gross Profit Growth % | 8.1% | -5.33% | 2.19% | -17.5% | 39.7% | 53.46% | 60.91% | -96.03% | 1546.84% | - |
Operating Expenses | 26.09M | 23.7M | 29.24M | 41.32M | 80.97M | 137.64M | 224.81M | 104.36M | 39.6M | 46.27M |
OpEx % of Revenue | 274.47% | 197.53% | 288.62% | 485.99% | 450.34% | 495.08% | 622.47% | 339.11% | 138.9% | - |
Selling, General & Admin | 14.08M | 14.22M | 20.16M | 0 | 58.49M | 88.6M | 94.96M | 51.85M | 28.22M | 34.13M |
SG&A % of Revenue | 148.13% | 118.5% | 198.98% | - | 325.29% | 318.67% | 262.93% | 168.49% | 99% | - |
Research & Development | 12.01M | 9.48M | 9.08M | 10.26M | 22.48M | 49.05M | 54.03M | 24.8M | 11.37M | 12.14M |
R&D % of Revenue | 126.35% | 79.03% | 89.65% | 120.62% | 125.05% | 176.42% | 149.61% | 80.59% | 39.9% | - |
Other Operating Expenses | 0 | 0 | 0 | 31.07M | 0 | 0 | 75.82M | 27.7M | 0 | 0 |
Operating Income | -23.22M▲ 0% | -20.42M▲ 12.1% | -25.87M▼ 26.7% | -38.55M▼ 49.0% | -77.1M▼ 100.0% | -131.7M▼ 70.8% | -215.25M▼ 63.4% | -103.98M▲ 51.7% | -33.34M▲ 67.9% | -32.77M▲ 0% |
Operating Margin % | -244.28% | -170.12% | -255.44% | -453.38% | -428.79% | -473.7% | -595.98% | -337.87% | -116.95% | -114.03% |
Operating Income Growth % | -9.69% | 12.08% | -26.74% | -48.99% | -100% | -70.81% | -63.44% | 51.69% | 67.94% | - |
EBITDA | -21.71M | -19.09M | -24.75M | -37.07M | -73.73M | -121.6M | -201.54M | -89.76M | -23.61M | -23.27M |
EBITDA Margin % | -228.46% | -159.11% | -244.31% | -435.99% | -410.05% | -437.38% | -558.03% | -291.65% | -82.81% | -80.96% |
EBITDA Growth % | -8.28% | 12.07% | -29.6% | -49.8% | -98.89% | -64.92% | -65.74% | 55.46% | 73.7% | 65.62% |
D&A (Non-Cash Add-back) | 1.5M | 1.32M | 1.13M | 1.48M | 3.37M | 10.1M | 13.71M | 14.23M | 9.73M | 9.51M |
EBIT | -22.76M | -17.1M | -27.51M | -37.05M | -77.22M | -130.41M | -227.31M | -111.69M | -33.34M | -32.77M |
Net Interest Income | -590.93K | -1.38M | -2.29M | -2.52M | -691K | 1.21M | -1.81M | 1.81M | 813K | 758K |
Interest Income | 0 | 0 | 0 | 0 | 236K | 1.51M | 3.31M | 2.1M | 1.11M | 1.04M |
Interest Expense | 590.93K | 1.38M | 2.29M | 2.52M | 927K | 298K | 5.12M | 289K | 298K | 286K |
Other Income/Expense | -128K | 1.93M | -3.92M | -2.53M | -1.05M | 986K | -17.19M | -8M | 7.01M | 1.24M |
Pretax Income | -23.35M▲ 0% | -18.48M▲ 20.8% | -29.79M▼ 61.2% | -41.08M▼ 37.9% | -78.15M▼ 90.3% | -130.71M▼ 67.3% | -232.43M▼ 77.8% | -111.98M▲ 51.8% | -26.33M▲ 76.5% | -31.53M▲ 0% |
Pretax Margin % | -245.63% | -154% | -294.13% | -483.09% | -434.64% | -470.15% | -643.57% | -363.87% | -92.35% | -109.7% |
Income Tax | 18.55K | 15.51K | 21.05K | 29K | -5.72M | 1.88M | 62K | 33K | 67K | 69K |
Effective Tax Rate % | -0.08% | -0.08% | -0.07% | -0.07% | 7.32% | -1.44% | -0.03% | -0.03% | -0.25% | -0.22% |
Net Income | -23.37M▲ 0% | -18.5M▲ 20.8% | -29.82M▼ 61.2% | -41.11M▼ 37.9% | -72.44M▼ 76.2% | -132.6M▼ 83.1% | -232.49M▼ 75.3% | -112.02M▲ 51.8% | -26.39M▲ 76.4% | -31.6M▲ 0% |
Net Margin % | -245.82% | -154.13% | -294.34% | -483.43% | -402.84% | -476.93% | -643.74% | -363.98% | -92.59% | -109.95% |
Net Income Growth % | -23.96% | 20.84% | -61.19% | -37.87% | -76.22% | -83.06% | -75.34% | 51.82% | 76.44% | 62.25% |
Net Income (Continuing) | -23.37M | -18.5M | -29.82M | -41.11M | -72.44M | -132.6M | -232.49M | -112.02M | -26.39M | -31.6M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 0.00▲ 0% | -94089.60▲ 0% | -71662.20▲ 23.8% | -14194.80▲ 80.2% | -157.02▲ 98.9% | -267.71▼ 70.5% | -408.60▼ 52.6% | -88.13▲ 78.4% | -4.85▲ 94.5% | -5.80▲ 0% |
EPS Growth % | - | - | 23.84% | 80.19% | 98.89% | -70.49% | -52.63% | 78.43% | 94.5% | 89.87% |
EPS (Basic) | 0.00 | -94089.60 | -71662.20 | -14194.80 | -157.02 | -267.71 | -408.48 | -88.13 | -4.85 | - |
Diluted Shares Outstanding | 0 | 201 | 424 | 177.23K | 470.53K | 491.66K | 580.55K | 1.9M | 5.45M | 5.45M |
Basic Shares Outstanding | 0 | 201 | 424 | 177.23K | 470.53K | 491.66K | 580.38K | 1.9M | 5.45M | 5.45M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
BNGO Balance Sheet
Bionano Genomics, Inc. (BNGO) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 7.14M | 23.03M | 28.26M | 46.79M | 272.41M | 157.3M | 140.12M | 39.49M | 45.39M | 38.98M |
Cash & Short-Term Investments | 1.02M | 16.52M | 17.31M | 38.45M | 250.61M | 113.19M | 66.77M | 9.47M | 13.26M | 24.67M |
Cash Only | 1.02M | 16.52M | 17.31M | 38.45M | 24.57M | 5.09M | 17.95M | 9.17M | 2.99M | 13.69M |
Short-Term Investments | 0 | 0 | 0 | 0 | 226.04M | 108.09M | 48.82M | 302K | 10.27M | 10.98M |
Accounts Receivable | 3.35M | 4.51M | 6.33M | 2.77M | 5.32M | 7.5M | 9.66M | 4.77M | 5.2M | 4.13M |
Days Sales Outstanding | 128.73 | 137.3 | 228.23 | 119.12 | 108.01 | 98.41 | 97.64 | 56.62 | 66.58 | 55.1 |
Inventory | 1.69M | 1.07M | 3.44M | 3.31M | 12.39M | 29.76M | 22.89M | 11.12M | 5.45M | 5.31M |
Days Inventory Outstanding | 102.51 | 44.77 | 185.71 | 211.16 | 320.5 | 496.99 | 314.71 | 133.54 | 89.37 | 158.29 |
Other Current Assets | 550.06K | 458.82K | 457.06K | 462K | 1.38M | 2.41M | 36.09M | 12.32M | 21.48M | 4.86M |
Total Non-Current Assets | 3.01M | 1.78M | 1.95M | 13.66M | 104.69M | 150.2M | 74.28M | 37.18M | 28.2M | 25.83M |
Property, Plant & Equipment | 3.01M | 1.78M | 1.95M | 4.91M | 20.93M | 28.96M | 32.48M | 24.32M | 21.16M | 20.15M |
Fixed Asset Turnover | 3.16x | 6.75x | 5.20x | 1.73x | 0.86x | 0.96x | 1.11x | 1.27x | 1.35x | 1.30x |
Goodwill | 0 | 0 | 0 | 7.17M | 56.16M | 77.29M | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 1.48M | 26.84M | 41.14M | 33.97M | 9.71M | 4.34M | 3M |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 103K | 749K | 2.81M | 7.83M | 3.15M | 2.69M | 2.68M |
Total Assets | 10.15M▲ 0% | 24.8M▲ 144.5% | 30.21M▲ 21.8% | 60.45M▲ 100.1% | 377.1M▲ 523.8% | 307.5M▼ 18.5% | 214.4M▼ 30.3% | 76.67M▼ 64.2% | 73.58M▼ 4.0% | 64.8M▲ 0% |
Asset Turnover | 0.94x | 0.48x | 0.34x | 0.14x | 0.05x | 0.09x | 0.17x | 0.40x | 0.39x | 0.39x |
Asset Growth % | -31.39% | 144.48% | 21.79% | 100.11% | 523.82% | -18.46% | -30.28% | -64.24% | -4.03% | -72.13% |
Total Current Liabilities | 16.65M | 4.52M | 26.37M | 8.95M | 21.84M | 35.88M | 100.03M | 37.34M | 22.94M | 21.23M |
Accounts Payable | 2.3M | 1.35M | 2.7M | 2.93M | 10.77M | 12.53M | 10.38M | 6.96M | 5.59M | 5.06M |
Days Payables Outstanding | 139.39 | 56.64 | 145.56 | 186.64 | 278.63 | 209.31 | 142.76 | 83.6 | 91.7 | 137.03 |
Short-Term Debt | 6.73M | 0 | 20.08M | 0 | 0 | 0 | 69.8M | 20.36M | 946K | 11.04M |
Deferred Revenue (Current) | 211.7K | 271K | 357.49K | 416K | 1.51M | 888K | 800K | 1.13M | 0 | 2.29M |
Other Current Liabilities | 3.9M | 2.13M | 2.07M | 3.36M | 4.53M | 16.38M | 13.96M | 3M | 16.13M | 1.37M |
Current Ratio | 0.43x | 5.09x | 1.07x | 5.23x | 12.47x | 4.38x | 1.40x | 1.06x | 1.98x | 1.84x |
Quick Ratio | 0.33x | 4.85x | 0.94x | 4.86x | 11.91x | 3.55x | 1.17x | 0.76x | 1.74x | 1.59x |
Cash Conversion Cycle | 91.85 | 125.44 | 268.38 | 143.64 | 149.88 | 386.09 | 269.59 | 106.56 | 64.25 | 76.36 |
Total Non-Current Liabilities | 43.72M | 10.14M | 227.13K | 16.42M | 18.14M | 22.22M | 18.22M | 3.95M | 6.22M | 6.11M |
Long-Term Debt | 0 | 9.03M | 0 | 16.32M | 0 | 0 | 0 | 0 | 5.97M | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 8.93M | 9.12M | 7.17M | 3.68M | 0 | 12.19M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 43.58M | 808.37K | 44.48K | 0 | 9.07M | 12.97M | 10.89M | 0 | 0 | 0 |
Total Liabilities | 60.37M | 14.67M | 26.59M | 25.37M | 39.98M | 58.1M | 118.25M | 41.3M | 29.16M | 27.34M |
Total Debt | 6.73M | 9.03M | 20.08M | 16.32M | 10.7M | 11.67M | 79.41M | 27.3M | 6.92M | 17.01M |
Net Debt | 5.71M | -7.49M | 2.77M | -22.12M | -13.88M | 6.58M | 61.47M | 18.12M | 3.92M | 3.32M |
Debt / Equity | - | 0.89x | 5.56x | 0.47x | 0.03x | 0.05x | 0.83x | 0.77x | 0.16x | 0.45x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.73x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.14x |
Interest Coverage | -38.51x | -12.38x | -12.03x | -14.71x | -83.31x | -437.63x | -44.41x | -386.49x | -111.88x | -114.58x |
Total Equity | -50.23M▲ 0% | 10.14M▲ 120.2% | 3.61M▼ 64.4% | 35.08M▲ 870.8% | 337.12M▲ 860.9% | 249.4M▼ 26.0% | 96.16M▼ 61.4% | 35.38M▼ 63.2% | 44.42M▲ 25.6% | 37.46M▲ 0% |
Equity Growth % | -84.26% | 120.18% | -64.35% | 870.8% | 860.94% | -26.02% | -61.44% | -63.21% | 25.58% | -38.29% |
Book Value per Share | - | 50556.57 | 8515.47 | 197.95 | 716.46 | 507.26 | 165.63 | 18.59 | 8.16 | 6.88 |
Total Shareholders' Equity | -50.23M | 10.14M | 3.61M | 35.08M | 337.12M | 249.4M | 96.16M | 35.38M | 44.42M | 37.46M |
Common Stock | 8 | 1K | 3.43K | 19K | 29K | 3K | 0 | 0 | 1K | 1K |
Retained Earnings | -54.27M | -72.76M | -102.58M | -143.68M | -216.12M | -348.71M | -581.21M | -693.23M | -719.62M | -727.92M |
Treasury Stock | -4.04M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -3.92M | -5.16M | 0 | 0 | -539K | -1.12M | 23K | 27K | 17K | 12K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BNGO Cash Flow Statement
Bionano Genomics, Inc. (BNGO) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -20.82M | -19.94M | -29.53M | -38.31M | -71.93M | -124.82M | -125.18M | -68.92M | -16.34M | -19.3M |
Operating CF Margin % | -219.02% | -166.19% | -291.52% | -450.59% | -400.02% | -448.95% | -346.61% | -223.95% | -57.33% | - |
Operating CF Growth % | 11.4% | 4.2% | -48.06% | -29.75% | -87.73% | -73.53% | -0.29% | 44.94% | 76.28% | 68.98% |
Net Income | -23.37M | -18.5M | -29.82M | -41.11M | -72.44M | -132.6M | -232.49M | -112.02M | -26.39M | -31.6M |
Depreciation & Amortization | 1.5M | 1.32M | 1.13M | 1.48M | 3.37M | 9.84M | 13.91M | 14.23M | 9.73M | 9.61M |
Stock-Based Compensation | 382.83K | 1.31M | 1.35M | 1.55M | 9.72M | 22.42M | 15.18M | 9.74M | 4.53M | 2.01M |
Deferred Taxes | 479.01K | -2.46M | 1.9M | 0 | -5.78M | 1.76M | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 96.58K | 750.47K | 883.27K | 3.2M | 848K | 1.7M | 92.99M | 14.73M | -4.73M | 2.82M |
Working Capital Changes | 85.1K | -2.37M | -4.97M | -3.44M | -7.65M | -27.94M | -14.77M | 4.4M | 514K | -2.14M |
Change in Receivables | -1.77M | -900.12K | -2.37M | 2.09M | -493K | -2.25M | -2.3M | 4.14M | -448K | -779K |
Change in Inventory | -336.05K | -418.98K | -3.64M | -4.2M | -15.93M | -23.68M | -4.15M | -587K | 4.92M | 3.7M |
Change in Payables | 1.54M | -954.38K | 1.36M | -1.81M | 6.78M | 1.95M | -2M | -3.42M | -1.37M | -1.5M |
Cash from Investing | -1.02M | -331.72K | -61.06K | -2.45M | -278.06M | 82.77M | 24.16M | 73.84M | -12.75M | 6.78M |
Capital Expenditures | -1.02M | -331.72K | -61.06K | 0 | -1.46M | -3.2M | -1.69M | -103K | 0 | 0 |
CapEx % of Revenue | 10.71% | 2.76% | 0.6% | - | 8.12% | 11.51% | 4.68% | 0.33% | - | 0% |
Acquisitions | 0 | 0 | 0 | -2.45M | -49.09M | -31.34M | 96K | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | -607K | 618K | 0 | 0 | 0 | 0 |
Cash from Financing | 17.61M | 35.78M | 30.38M | 61.9M | 336.11M | 23.01M | 113.81M | -13.69M | 24.04M | 13.8M |
Debt Issued (Net) | 0 | 16.38M | 9.82M | -4.72M | -15.01M | -36K | 70.95M | -48.06M | -4.95M | -3.45M |
Equity Issued (Net) | 17.59M | 19.39M | 19.56M | 39.93M | 342.71M | 23.13M | 57.7M | 44.43M | 28.98M | 17.36M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 14.29K | 3.5K | 1M | 26.69M | 8.4M | -85K | -14.84M | -10.06M | 0 | -104K |
Net Change in Cash | -4.23M▲ 0% | 15.5M▲ 466.6% | 788.64K▼ 94.9% | 21.14M▲ 2580.3% | -13.88M▼ 165.7% | -19.08M▼ 37.5% | 12.86M▲ 167.4% | -8.78M▼ 168.3% | -5.06M▲ 42.3% | 10.07M▲ 0% |
Free Cash Flow | -21.84M▲ 0% | -20.28M▲ 7.1% | -29.59M▼ 45.9% | -38.31M▼ 29.5% | -73.39M▼ 91.5% | -128.12M▼ 74.6% | -126.87M▲ 1.0% | -69.03M▲ 45.6% | -16.34M▲ 76.3% | -19.3M▲ 0% |
FCF Margin % | -229.73% | -168.95% | -292.12% | -450.59% | -408.14% | -460.82% | -351.29% | -224.28% | -57.33% | -67.15% |
FCF Growth % | 12.12% | 7.14% | -45.94% | -29.48% | -91.54% | -74.58% | 0.97% | 45.59% | 76.32% | 57.19% |
FCF per Share | - | -101117.44 | -69728.55 | -216.19 | -155.97 | -260.58 | -218.54 | -36.28 | -3.00 | -3.54 |
FCF Conversion (FCF/Net Income) | 0.89x | 1.08x | 0.99x | 0.93x | 0.99x | 0.94x | 0.54x | 0.62x | 0.62x | 0.61x |
Interest Paid | 0 | 0 | 0 | 1.25M | 1.91M | 298K | 1.65M | 10.65M | 0 | 442K |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BNGO Key Ratios
Bionano Genomics, Inc. (BNGO) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -182.46% | -433.64% | -212.46% | -38.92% | -45.21% | -134.56% | -170.33% | -66.15% | -71.38% |
Return on Invested Capital (ROIC) | - | -579.1% | -429.75% | -298.92% | -34.4% | -34.11% | -78.06% | -73.88% | -49.1% | -48.04% |
Gross Margin | 36.55% | 27.41% | 33.18% | 32.61% | 21.55% | 21.38% | 26.49% | 1.23% | 21.95% | 46.97% |
Net Margin | -245.82% | -154.13% | -294.34% | -483.43% | -402.84% | -476.93% | -643.74% | -363.98% | -92.59% | -109.95% |
Debt / Equity | - | 0.89x | 5.56x | 0.47x | 0.03x | 0.05x | 0.83x | 0.77x | 0.16x | 0.45x |
Interest Coverage | -38.51x | -12.38x | -12.03x | -14.71x | -83.31x | -437.63x | -44.41x | -386.49x | -111.88x | -114.58x |
FCF Conversion | 0.89x | 1.08x | 0.99x | 0.93x | 0.99x | 0.94x | 0.54x | 0.62x | 0.62x | 0.61x |
Revenue Growth | 39.93% | 26.26% | -15.59% | -16.06% | 111.47% | 54.62% | 29.9% | -14.79% | -7.37% | 0.96% |
Related:BNGO Dividend History·BNGO Revenue History·BNGO Price History·BNGO P/E History·BNGO Financial Ratios·BNGO Institutional Holders
BNGO SEC Filings & Documents
Bionano Genomics, Inc. (BNGO) SEC filings — annual & quarterly reports (10-K, 10-Q)
BNGO Frequently Asked Questions
Bionano Genomics, Inc. (BNGO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Bionano Genomics, Inc. (BNGO) reported $28.7M in revenue for fiscal year 2025. This represents a 323% increase from $6.8M in 2016.
Bionano Genomics, Inc. (BNGO) saw revenue decline by 7.4% over the past year.
Bionano Genomics, Inc. (BNGO) reported a net loss of $31.6M for fiscal year 2025.
Dividend & Returns
Bionano Genomics, Inc. (BNGO) has a return on equity (ROE) of -66.2%. Negative ROE indicates the company is unprofitable.
Bionano Genomics, Inc. (BNGO) had negative free cash flow of $19.3M in fiscal year 2025, likely due to heavy capital investments.